Siste oppdatering :
26/03/2024
Kreft narkotika   Etoposide  
Injeksjon
Mikstur
Oppløsningsstabilitet Stabilitet i blandinger Faktorer som påvirker stabiliteten Kompatibilitet Administrasjonsmåte Referanser Pdf
   Kjemisk struktur  

Handelsnavn   Handelsnavn     

Handelsnavn er veiledende og sammensetning av hjelpestoffer kan være forskjellig avhengig av land og produsent

Eposin Belgia, Colombia, Malaysia, Norge, Storbritannia, Sverige, Sør-Afrika
Etocris Argentina, Chile, Peru
Etolon India
Etomedac Luxembourg, Tyskland
Etonolver Venezuela
Etoposide Frankrike, Hellas, Nederland
Etosid Egypt, India, Malaysia
Eunades Brasil
Euvaxon Argentina
Exitop Finland, Sverige, Tyskland
Fytosid Egypt, India, Malaysia
Lastet De forente arabiske emirater, Egypt, Iran, Italia, Polen, Tyrkia, Ungarn
Onkoposid Tyskland
Riboposid Tyskland
Sedol Peru
Toposin Nederland
Tosuben Mexico
Vepesid Australia, Belgia, Canada, Colombia, Danmark, Egypt, Finland, Hellas, Irland, Italia, Kroatia, Luxembourg, Nederland, Polen, Saudi-Arabia, Slovenia, Spania, Sveits, Sør-Afrika, Tyrkia, Tyskland, Ungarn, USA, Østerrike
Vepeside Marokko, Tunisia
Referanser   Injeksjon   Referanser : Etoposide  
Type Publikasjon
3 Journal Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
57 Journal Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
81 Journal Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Journal Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
85 Journal Trissel LA, Bready BB.
Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 1716-1719.
91 Journal Lober CA, Dollard PA.
Visual compatibility of gallium nitrate with selected drugs during Y-site injection.
Am J Hosp Pharm 1993 ; 50: 1208-1210.
99 Journal Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
140 Journal Pearson SD, Trissel LA.
Leaching of diethylhexyl phthalate from polyvinyl chloride containers by selected drugs and formulation components.
Am J Hosp Pharm 1993 ; 50: 1405-1409.
150 Journal Aujoulat P, Coze C, Braguer D, Raybaud C.
Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens.
J Pharm Clin 1993 ; 12: 31-35.
152 Journal Chevrier R, Sautou V, Pinon V, Demecop F, Chopineau J.
Stability and compatibility of a mixture of the anti-cancer drugs etoposide, cytarabine and daunorubicine for infusion.
Pharm Acta Helv 1995 ; 70: 141-148.
161 Journal Barthes DM, Rochard EB, Pouliquen IJ, Rabouan SM, Courtois PY.
Stability and compatibility of etoposide in 0.9% sodium chloride injection in three containers.
Am J Hosp Pharm 1994 ; 51: 2706-2709.
169 Journal Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 Journal Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
184 Journal Stewart JT, Warren FW, King DT, Fox JL.
Stability of ondansetron hydrochloride and five antineoplasic medications.
Am J Health-Syst Pharm 1996 ; 53: 1297-1300.
244 Journal Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 Journal Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Journal Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
307 Journal Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
331 Journal Marquardt ED.
Visual compatibility of hydroxyzine hydrochloride with various antineoplasic agents.
Am J Hosp Pharm 1988 ; 45: 2127.
334 Journal Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Journal Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
417 Journal Stewart CF, Hampton EM.
Stability of cisplatin and etoposide in intravenous admixtures.
Am J Hosp Pharm 1989 ; 46: 1400-1404.
482 Journal Beijnen JH, Beijnen-Bandhoe U, Dubbelman AC, Van Gijn R, Underberg WJM.
Chemical and physical stability of etoposide and teniposide in commonly used infusion fluids.
J Parenter Sci Technol 1991 ; 45: 108-112.
491 Journal Turowski RC, Durthaler JM.
Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2181-2184.
492 Journal Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
504 Journal Hamon M, Plas-Remoissenet D, Kubab-Alajati S.
Etude de la stabilité dans des solutions diluées destinées à la perfusion de deux antimitotiques dérivés de la podophyllotoxine : l’étoposide (VP 16), le téniposide (VM 26).
Sci Tech Pharm 1987 ; 3: 33-40.
643 Journal Seargeant LE, Kobrinsky NL, Sus CJ, Nazeravich DR.
In vitro stability and compatibility of daunorubicin, cytarabine, and etoposide.
Cancer Treat Rep 1987 ; 71: 1189-1192.
905 Journal Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
1026 Journal Mayron D, Gennaro AR.
Stability and compatibility of topotecan hydrochloride with selected drugs.
Am J Health-Syst Pharm 1999 ; 56: 875-881.
1033 Journal Wolfe JL, Thoma LA, Du C, Goldspiel BR, Gallelli JF, Grimes GJ, Potti GK.
Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection.
Am J Health-Syst Pharm 1999 ; 56: 985-989.
1423 Journal Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1496 Journal Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428.
1520 Labratorium Etude de stabilité des médicaments en Ecoflac®
B Braun 2001
1613 Journal Lepage R, Walker SE, Godin J.
Stability and compatibility of etoposide in normal saline.
Can J Hosp Pharm 2000 ; 53: 338-345.
1722 Journal Gras C, Sautou-Miranda V, Bagel-Boithias S, Brigas F, Chopineau J.
Compatibility of etoposide solution with polyvinyl chloride and low density polyethylene containers and its stability in different storage conditions.
EJHP 2002 ; 2: 33-40.
1730 Journal Björkman S, Roth B.
Chemical compatibility of mitoxantrone and etoposide (VP-16).
Act Pharm Nord 1991 ; 3: 251.
1819 Journal Demoré B, Vigneron J, Perrin A, Hoffman MA, Hoffman M.
Leaching of diethyl hexyl phtalate from polyvinyl chloride bags into intravenous etoposide solution.
J Clin Pharm Ther 2002 ; 27: 139-142.
1895 Journal Bourdeaux D, Sautou-Miranda V, Bagel-Boithias S, Boyer A, Chopineau J.
Analysis by liquid chromatography and infrared spectrometry of di(2-ethylhexyl)phtalate released by multilayer infusion tubing.
J Pharm Biomed Anal 2004 ; 35: 57-64.
1984 Journal Bagel-Boithias S, Sautou-Miranda V, Bourdeaux D, Tramier V, Boyer A, Chopineau J.
Leaching of diethylhexyl phtalate from multilayer tubing into etoposide infusion solutions.
Am J Health-Syst Pharm 2005 ; 62: 182-188.
2108 Journal Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232.
2167 Journal Joel SP, Clark PI, Slevin ML.
Stability of the iv and oral formulations of etoposide in solution.
Cancer Chemother Pharmacol 1995 ; 37, 1: 117-124.
3574 Labratorium Ondansetron - Résumé des caractéristiques du produit
Accord Healthcare France SAS 2013
3670 Journal Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
4024 Plakat Sadou Yaye H, Rieber Z, HassaniI L, Hoffmann-Martinot C, Babiard M, Aouti H, Bellanger A, Tilleul P.
Pénurie mondiale d'Etopophos et conséquences pratiques : Intérêt des études de stabilité dans le choix d'un générique.
SFPO Congress 2017 - Nantes 2017
4125 Journal D'Huart E, Vigneron J, Lider P, Demoré B.
Physicochemical stability of etoposide diluted at range concentrations between 0.38 and 1.75 mg/mL in polyolefin bags.
EJHP 2020 ; 27, 1: 43-48.
4304 Journal Klasen K, Kessari R, Mercier L, Valade C, Grill J, Desmaris R, Paci A.
Stability of Etoposide Solutions in Disposable Infusion Devices for Day Hospital Cancer Practices.
Drugs R D 2014 ; 14:13?23.
4352 Journal Li J, Yao C, Xu Y, Ping P, Yin H, Sun Y.
In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag.
J Clin Pharm Ther 2019 ; 44: 875-882.
4369 Journal Sadou Yayé H, Hassani L, Secrétan PH, Babiard M, Aouati H, Bellanger A, Tilleul P, Yagoubi N, Do B, Rietveld I.
Physical and chemical stability of a generic etoposide formulation as an alternative to etoposide phosphate
J Pharm Biomed Anal 2020 ;178:112896

  Mentions Légales